Company: TVRD
Filing Date: 2025-01-21
Form Type: 425
Source: 0001104659-25-004749
Chunk: 2

Company: Tvardi Therapeutics, Inc.
Filing Date: 2025-01-21
Form: 425
Chunk 2
---
isting determination
if issued, the ability of the Company to comply with the listing requirements of Nasdaq and the ability of the parties to consummate the
Merger on the expected timeline or at all.

Because such statements are
subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements.
These forward-looking statements are subject to a number of risks, including those factors discussed in the Company’s filings with
the Securities and Exchange Commission, including the “Risk Factors” section of the Company’s Annual Report on Form
10-K for the year ending December 31, 2023, and its other documents subsequently filed with or furnished to the Securities and Exchange
Commission, including its Form 10-Q for the quarter ended September 30, 2024. All forward-looking statements contained in this Current
Report on Form 8-K speak only as of the date on which they were made. The Company undertakes no obligation to update such statements to
reflect events that occur or circumstances that exist after the date on which they were made, except as required by law.

Additional Information and Where to Find It

This Current Report on Form
8-K relates to a proposed acquisition transaction between the Company and Tvardi. In connection with the proposed transaction, the Company
has filed with the Securities and Exchange Commission (the “SEC”) a registration statement on Form S-4 that contains a preliminary
proxy statement and preliminary prospectus. The Company may also file other documents with the SEC regarding the proposed transaction.
THE COMPANY URGES INVESTORS AND STOCKHOLDERS TO READ THESE MATERIALS CAREFULLY AND IN THEIR ENTIRETY WHEN THEY BECOME AVAILABLE BECAUSE
THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT THE COMPANY, TVARDI, THE PROPOSED TRANSACTION AND RELATED MATTERS. Stockholders are and
will be able to obtain free copies of the preliminary proxy statement, preliminary prospectus and other documents filed by the Company
with the SEC (when they become available) through the website maintained by the SEC at www.sec.gov. In addition, stockholders
are or will be able to obtain free copies of the preliminary proxy statement, preliminary prospectus and other documents filed by the
Company with the SEC by contacting Investor Relations by email at investor@caratherapeutics.com. Stockholders are urged to
read the preliminary proxy statement, preliminary prospectus and the other relevant materials when they become available before making
any voting or investment decision with respect to the proposed transaction.

Participants